Cargando…

Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice

The accuracy of pharmacokinetic (PK)-guided dosing depends on the clinical and laboratory data used to construct a population PK model, as well as the patient’s individual PK profile. This review provides a detailed overview of data used for published population PK models for factor VIII (FVIII) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goedhart, Tine M. H. J., Bukkems, Laura H., Zwaan, C. Michel, Mathôt, Ron A. A., Cnossen, Marjon H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945640/ https://www.ncbi.nlm.nih.gov/pubmed/34496017 http://dx.doi.org/10.1182/bloodadvances.2021005096

Ejemplares similares

Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation
por: Bukkems, Laura H., et al.
Publicado: (2023)

Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?
por: Goedhart, Tine M.H.J., et al.
Publicado: (2022)

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
por: Preijers, Tim, et al.
Publicado: (2020)

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates
por: Preijers, Tim, et al.
Publicado: (2021)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
por: Bukkems, Laura H., et al.
Publicado: (2023)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
por: Goedhart, Tine M.H.J., et al.
Publicado: (2022)

Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia
por: van Moort, Iris, et al.
Publicado: (2021)

Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study
por: Heijdra, Jessica M, et al.
Publicado: (2022)

Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic‐pharmacodynamic model for patients with haemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients
por: Preijers, Tim, et al.
Publicado: (2021)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
por: de Jager, Nico C. B., et al.
Publicado: (2019)

Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
por: Iorio, Alfonso, et al.
Publicado: (2018)

In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients
por: Preijers, T., et al.
Publicado: (2021)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

Patients’ and health care providers’ perspectives on quality of hemophilia care in the Netherlands: a questionnaire and interview study
por: Brands, Martijn R., et al.
Publicado: (2023)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A
por: Donners, Anouk, et al.
Publicado: (2023)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Application of SHAP values for inferring the optimal functional form of covariates in pharmacokinetic modeling
por: Janssen, Alexander, et al.
Publicado: (2022)

Overview of Project BETA: Best practices in Evaluation and Treatment of Agitation
por: Holloman, Garland H, et al.
Publicado: (2012)

Cloud security: overview and best practices
por: Bond, James
Publicado: (2015)

Deep compartment models: A deep learning approach for the reliable prediction of time‐series data in pharmacokinetic modeling
por: Janssen, Alexander, et al.
Publicado: (2022)

Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance
por: Byon, W, et al.
Publicado: (2013)

Generic PROMIS item banks in adults with hemophilia for patient‐reported outcome assessment: Feasibility, measurement properties, and relevance
por: Kuijlaars, Isolde A. R., et al.
Publicado: (2021)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
por: Chen, Zhenping, et al.
Publicado: (2021)

Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients
por: van Moort, Iris, et al.
Publicado: (2020)

Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model
por: Kloos, Robin Q.H., et al.
Publicado: (2020)

Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model
por: Kloos, Robin Q.H., et al.
Publicado: (2023)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
por: Teitel, Jerome, et al.
Publicado: (2021)

Practice of Iranian Adolescents with Hemophilia in Prevention of Complications of Hemophilia
por: Valizadeh, Leila, et al.
Publicado: (2015)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
por: Croteau, Stacy E., et al.
Publicado: (2020)

Planning your cloud architecture: overview and best practices
por: Bond, James
Publicado: (2018)

Focusing in on use of pharmacokinetic profiles in routine hemophilia care
por: Croteau, Stacy E., et al.
Publicado: (2018)

Adoption of Machine Learning in Pharmacometrics: An Overview of Recent Implementations and Their Considerations
por: Janssen, Alexander, et al.
Publicado: (2022)

Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set
por: van Balen, Erna C., et al.
Publicado: (2021)

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
por: Keizer, Ron J, et al.
Publicado: (2015)

Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study
por: Schütte, Lisette M, et al.
Publicado: (2019)

Psychometrics of the patient-reported outcomes measurement information system measures in hemophilia: the applicability of the pediatric item banks
por: Teela, Lorynn, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h0her1c7litrlsasom0jp638o6